Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Chou

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across CarcinomasShuang G Zhao, William S Chen, Rajdeep Das, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Science (New York, N.Y.)|March 12, 2026
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancerCorleone S Delaveris, Rita P Loudermilk, Apurva Pandey, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Molecular Cancer Therapeutics|September 27, 2024
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate CancerNiranjan Meher, Anil P Bidkar, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT TrialCharles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Cancer Research|November 9, 2022
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate CancerJonathan Chou, Emily A Egusa, Sinan Wang, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Identification and Characterization of PLUTO-201, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate CancerHui Li, Noah S Younger, Bhavna Malik, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across CarcinomasShuang G Zhao, William S Chen, Rajdeep Das, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Science (New York, N.Y.)|March 12, 2026
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancerCorleone S Delaveris, Rita P Loudermilk, Apurva Pandey, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Molecular Cancer Therapeutics|September 27, 2024
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate CancerNiranjan Meher, Anil P Bidkar, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT TrialCharles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Cancer Research|November 9, 2022
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate CancerJonathan Chou, Emily A Egusa, Sinan Wang, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Identification and Characterization of PLUTO-201, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate CancerHui Li, Noah S Younger, Bhavna Malik, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Pageof 9